Q-omics provides the consensus-scored TRARG1 profile across patient tissues and cancer cell-line models. TRARG1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TRARG1 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, TRARG1 RNA expression shows 7,989 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight ACC, HNSC, and BRCA as cancer lineages where TRARG1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRARG1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRARG1 survival associations across molecular data types. TRARG1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRARG1 RNA expression–survival associations across cancer types. High TRARG1 expression shows unfavorable associations in ACC, but favorable associations in BRCA, PAAD, LIHC, UCS and THCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TRARG1 RNA expression.
This table summarizes TRARG1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and OV for protein.
This table ranks reproducible tumor–normal expression differences for TRARG1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRARG1 shows lower tumor expression in HNSC, KIRC, BRCA, STAD, UCEC and LUSC. The HNSC box plot shows higher TRARG1 RNA expression in normal versus tumor tissue (log2 FC = −1.214, t-test p < 0.001).
This table shows molecular features associated with TRARG1 in patient tissues and cancer cell lines. In patient samples, TRARG1 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, TRARG1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
